Andrea Schietinger: Overview

The goal of our laboratory is to understand when, why, and how such tumor-specific T cells become unresponsive to tumors. We develop genetic cancer mouse models that mimic cancer development in patients, investigate tumor-specific T cell responses over the course of tumor development, and define the molecular and epigenetic mechanisms that are responsible for the failure to control and eliminate tumors.

Based on the findings from our mouse models, and together with our clinical colleagues at Memorial Sloan Kettering, we then work to define the “dysfunctional code” in human tumor-specific T cells and design strategies to override cell-intrinsic T cell dysfunction programs to improve cancer immunotherapy. Detailed information about our research is available at